To embed, copy and paste the code into your website or blog:
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Shire LLC v. Neos Therapeutics, Inc.
3:13-cv-01452; filed April 11, 2013 in the Northern District of Texas
Infringement of U.S. Patent Nos. RE42,096 ("Oral Pulsed Dose Drug Delivery System," issued February 1, 2011) and RE41,148 (same title, issued February 23, 2010) following a Paragraph IV certification as part of Neos filing of an NDA (under § 505(b)(2) of the Food, Drug and Cosmetic Act) to manufacture a generic version of Shire's Adderall XR® (a combination of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate, used to treat attention deficit hyperactivity disorder). View the complaint here.
Japanese Foundation for Cancer Research v. Rea et al.
1:13-cv-00412; filed April 1, 2013 in the Eastern District of Virginia
• Plaintiff: Japanese Foundation for Cancer Research
• Defendants: Teresa Stanek Rea; United States Patent and Trademark Office
Judicial review of the USPTO's refusal to grant a petition for withdrawal of an unauthorized disclaimer of the remaining term of U.S. Patent No. 6,194,187 ("Apoptosis-inducing Protein and Gene Encoding the Same," issued February 27, 2001). View the complaint here.
Topics: Infringement, Patents, Pharmaceutical Patents
Published In: Civil Procedure Updates, Intellectual Property Updates, Science, Computers & Technology Updates
At McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB"), we provide creative, pragmatic business...
View Profile »
Back to Top